Data from the UALCAN database indicated that TMED9 protein levels were elevated in breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), clear cell renal cell carcinoma (ccRCC), uterine corpus endometrial carcinoma (UCEC), lung adenocarcinoma (LUAD), and glioblastoma multiforme (GBM), whereas a significant downregulation was observed in pancreatic adenocarcinoma (PAAD) (Figure 1F, Supplementary Figure 1E). Here, TMED9 is linked to nonpapillary renal cell carcinoma.